Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eden vs Sprout Health

By GLP-1 ScorecardUpdated

Eden
Site position #16

Higher grade

Sprout Health
Site position #26

Lower grade

Score comparison

Eden has the higher recorded score — 81.6/100 to 79.8/100, but only just.

Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase. Sprout Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueSprout Health +5
85
90
Dose & formulationEden +4
86
82
Clinical oversightEven
55
55
Labs & monitoringEven
92
92
FulfillmentEden +15
93
78
Contract termsEden +6
90
84
Eden · top barSprout Health · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEdenSprout Health
WeighScore81.6/10079.8/100
GradeB−C+
Site position#16#26
SemaglutideAdvertised $99/mo bundle; linked membership terms conflict—confirm checkout$299/mo
TirzepatideAdvertised $129/mo bundle; linked membership terms conflict—confirm checkout$349/mo
CoverageAll 50 statesNot disclosed
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
Eden

Site position #16 · B−

FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.

Strengths

  • Current compounded offer includes medication and support
  • Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
  • Named pharmacy operation and partner network can be investigated

What to consider

  • Linked membership terms describe a separate fee model
  • Landing-page warranty and terms use different thresholds and conditions
  • FDA warning history remains relevant; a new offer does not establish resolution
Sprout Health

Site position #26 · C+

FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.

Strengths

  • LegitScript-certified with a listed address and contact line
  • Both compounded ($149 semaglutide / $199 tirzepatide) and a genuine brand-name Wegovy/Zepbound route
  • Low-friction intake — no labs and often no telehealth visit required

What to consider

  • Compounded semaglutide and tirzepatide are not FDA-approved
  • No oral or sublingual route — injectable only
  • Thin transparency — no named medical director, and state availability is quiz-gated
  • "No labs, no visit" convenience also means lighter clinical oversight

Featured provider

Eden

Eden scores 81.6/100 (B−). Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.

Commercial relationships affect this placement. The score comparison above is separate.

FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard